AZD7789
Advanced Solid Tumors
Key Facts
About AstraZeneca
AstraZeneca is a global biopharmaceutical leader with a mission to push the boundaries of science to deliver life-changing medicines. The company has achieved significant commercial success with 16 blockbuster drugs and a robust pipeline of 197 projects, underpinned by a 'Growth Through Innovation' strategy focused on disease biology, next-generation therapeutics, predictive clinical success, and clinical innovation. AstraZeneca's strategic integration of data science, AI, and novel therapeutic modalities positions it to maintain its competitive edge and address complex healthcare challenges across its core therapeutic areas.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |